Considering Gal9 in RA, substantial evidence has shown that its plasma levels positively correlate with increased disease activity and severity, as reflected by higher disease scores, elevated acute-phase reactants, greater treatment burden, and longer disease duration [30,41,42,43,44,45]. The gene discussed is LGALS9; the disease is rheumatoid arthritis.